

Palbociclib PALOMA-3

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Delayed deterioration in global QoL

Serious and disabling adverse effects



Other adjustments



Palbociclib PALOMA-3

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Patients with hormone receptor-positive, HER2-negative locally advanced or MBC who have received prior endocrine therapy (ET)
Experimental Arm: Palbociclib + Fulvestrant
Control Arm: Fulvestrant + placebo

